Skip to content

Your selection

Cart

Loading cart…

Subtotal—

Delivery and taxes are calculated at checkout.

Go to checkout View full cart

ABOUT / PSYCHEDELICSY

About PsychedelicSy

We make complex research, health information, and public policy easier to understand. Our educational pages separate established findings from open questions and link readers to the sources behind consequential claims.

Foundational Mission: The Research-Commerce Integration

PsychedelicSy emerged from frustration with unregulated psychedelic markets and the critical need for research-grade compounds in clinical settings. Founded by neuroscience researchers from Stanford University and UCLA, our company operates at the intersection of academic research and ethical commerce. We believe responsible access to quality-controlled psychedelic materials accelerates scientific understanding, therapeutic applications, and harm reduction practices.

Scientific Pedigree: Academic Origins

Our founding team includes Dr. Evelyn Chen (Stanford Neuroscience, PhD '18), Dr. Marcus Thorne (UCLA Psychopharmacology, PhD '20), and Dr. Sophia Rodriguez (Johns Hopkins Psychiatry, MD '19). These academic backgrounds inform our rigorous quality standards, research protocols, and ethical framework. We maintain active research collaborations that bridge academic institutions, clinical facilities, and commercial operations.

01

Research Collaboration Ecosystem

Our partnership network extends beyond basic supplier relationships to include:Joint research initiatives with Johns Hopkins Center for Psychedelic and Consciousness ResearchClinical trial support through Multidisciplinary Association for Psychedelic StudiesPharmacological research collaboration with Imperial College LondonQuality assurance protocols developed with Usona InstituteEthical sourcing frameworks established with Chacruna Institute

02

Quality Assurance Protocol Matrix

Every product undergoes a 12-point verification process:
- Third-party ISO 17025 laboratory analysis for potency verification
- High-performance liquid chromatography for alkaloid profiling
- Gas chromatography-mass spectrometry for purity assessment
- Microbial contamination screening exceeding USP standards
- Heavy metal detection at parts-per-billion sensitivity
- Pesticide residue analysis for agricultural contaminants
- Stability testing under various environmental conditions
- Shelf-life determination through accelerated aging studies
- Genetic verification through DNA barcoding for mushroom species
- Terroir analysis for region-specific potency characteristics
- Clinical safety profile assessment through literature review
- Dosage protocol validation against recent research findings

03

Ethical Sourcing Framework

We work exclusively with licensed cultivators who adhere to ethical production standards, including fair labor practices, sustainable cultivation methods, and environmental stewardship. Our supply chain maintains complete transparency from spore to product, with documentation verifying ethical sourcing, organic cultivation practices, and quality control at every stage.Research Contribution Portfolio
Beyond commercial operations, we fund and support:Phase II clinical trials for psilocybin-assisted therapyMicrodosing research through academic partnershipsHarm reduction education initiativesPsychedelic integration training programsPolicy reform advocacy based on scientific evidenceOur contributions have directly supported research published in New England Journal of Medicine, JAMA Psychiatry, and Nature Medicine, advancing understanding of psychedelic therapeutics for treatment-resistant depression, PTSD, addiction, and end-of-life anxiety.

What these pages do not do

They do not diagnose, treat, cure, or prevent health conditions, recommend a substance, or promise any outcome from research. For personal medical or legal questions, consult a qualified local professional.

Read our editorial standards and corrections policy, or contact the editorial team.